Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Conditions

• BRAF NP_004324.2:p.V600E
• BRAF V600K Mutation Present
• Thyroid Gland Anaplastic Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Dabrafenib — DRUG
  Given PO
• Intensity-Modulated Radiation Therapy — RADIATION
  Undergo IMRT
• Trametinib — DRUG
  Given PO

Study Details

This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.

Key Dates

Start date

Sep 14, 2020

Status verified

Apr 2026

Primary completion

Oct 5, 2027

Completion

Oct 5, 2027

Study Design

Enrollment

6 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (dabrafenib, trametinib, IMRT)
  See Detailed Description

Primary Outcome Measure

Maximum tolerated dose of combination therapy of dabrafenib and trametinib administered concurrently with intensity-modulated radiation therapy (IMRT) [ Time Frame: 1 year ]

Central Contacts

• Sasan Fazeli, MD
  626-359-8111
  [email protected]

Locations (3)

Find similar trials in Duarte, CA